SCHEMBL4597795

SCHEMBL4597795

CCOC(=O)Cc1ccc(N)c(I)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
GAA P10253 1/20 0.45
GFER P55789 1/20 0.45
CYP4Z1 Q86W10 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
LMNA P02545 3/20 0.40
PPIB P23284 1/20 0.40
PPIA P62937 1/20 0.40
PPID Q08752 1/20 0.40
PPIG Q13427 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19592643 0.88 ALDH1A1 (0.49) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL118588 0.85 ALDH1A1 (0.53) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL31287243 0.85 ALDH1A1 (0.53) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL5156693 0.84 SKP2 (0.49) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL7974514 0.84 ALDH1A1 (0.64) ALDH1A1GAAGFERSMN1; SMN2NPC1
SCHEMBL4029467 0.83 GAA (0.54) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL5169007 0.82 PSEN1 (0.46) SMN1; SMN2NPC1PKMNFKB1RAB9A
SCHEMBL5741782 0.82 SMN1; SMN2 (0.43) ALDH1A1GAACYP4Z1SMN1; SMN2NPC1
SCHEMBL9606643 0.81 ALDH1A1 (0.45) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL90470 0.81 CYP3A4 (0.49) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115052860-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-06-21 CN disclosed
US-RE49687-E1 Thienopyrimidine and thienopyridine compounds and methods of use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-10 US disclosed
US-RE49687-E1 Thienopyrimidine and thienopyridine compounds and methods of use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-10 US disclosed
US-RE49687-E1 Thienopyrimidine and thienopyridine compounds and methods of use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-10 US disclosed
US-20230116201-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-04-13 US disclosed
EP-4097084-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2022-12-07 EP disclosed
CN-115052860-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-09-13 CN disclosed
WO-2021154902-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-08-05 WO disclosed
WO-2021154902-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-08-05 WO disclosed
EP-3237396-B1 HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS GENFIT (FR) 2019-07-03 EP disclosed
WO-2016040330-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-03-17 WO disclosed
CN-1993120-B Arylacetic acids and related compounds for treatment of alzheimer's disease MERCK SHARP & DOHME BLURTON PETER 2010-05-05 CN disclosed
US-20080300261-A1 Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-12-04 US disclosed
EP-1773315-B1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (GB) 2008-01-16 EP disclosed
CN-1993120-A Arylacetic acids and related compounds for treatment of alzheimer's disease MERCK SHARP & DOHME BLURTON PE (GB) 2007-07-04 CN disclosed
EP-1773315-A1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE Merck Sharp & Dohme Limited (GB) 2007-04-18 EP disclosed
WO-2006008558-A1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2006-01-26 WO disclosed
US-6500837-B2 TREATING PARKINSON'S DISEASE WARNER-LAMBERT COMPANY 2002-12-31 US disclosed
US-20020068752-A1 Fused ring system containing indole as M4 selective aza-anthracene muscarinic receptor antagonists AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2002-06-06 US disclosed
EP-1191027-A1 Fused ring system containing indole as M4 selective aza-anthracene muscarinic receptor antagonists WARNER-LAMBERT COMPANY (US) 2002-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300261-A1 Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease PSEN2, PSEN1, NAT1 ALDH1A1 126/4885GAA 36/4885GFER 1346/4885
US-20020068752-A1 Fused ring system containing indole as M4 selective aza-anthracene muscarinic receptor antagonists CHRM1, CHRM4, CHRM2 ALDH1A1 1475/4885GAA 3658/4885GFER 173/4885
US-20230116201-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 ALDH1A1 1209/4885GAA 1782/4885GFER 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.